Jaskaran B Singh Selected Research

Esketamine

1/2022	Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
1/2022	Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
11/2021	The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
12/2020	Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
1/2020	Approval of esketamine for treatment-resistant depression.
1/2020	Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
1/2020	Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
1/2020	Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
1/2020	Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
10/2019	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jaskaran B Singh Research Topics

Disease

17	Treatment-Resistant Depressive Disorder 01/2022 - 01/2016
4	Headache (Headaches) 10/2019 - 01/2016
4	Dizziness (Lightheadedness) 10/2019 - 01/2018
4	Nausea 10/2019 - 01/2016
4	Bipolar Disorder (Manic Depressive Psychosis) 05/2011 - 02/2005
3	Major Depressive Disorder (Major Depressive Disorders) 01/2020 - 01/2006
3	Vertigo (Positional Vertigo) 10/2019 - 01/2019
2	Dysgeusia (Parageusia) 01/2019 - 01/2019
2	Mood Disorders (Mood Disorder) 06/2013 - 01/2006
1	Hypertension (High Blood Pressure) 01/2020
1	Tachycardia (Tachyarrhythmias) 01/2020
1	Sleepiness 01/2019
1	Ectopic Pregnancy 01/2018
1	Syncope (Fainting) 01/2018
1	Body Weight (Weight, Body) 08/2016
1	Mania (Manias) 09/2007
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 12/2006
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 12/2006
1	Feeding and Eating Disorders (Eating Disorder) 12/2006
1	Anxiety Disorders (Anxiety Disorder) 12/2006
1	Substance-Related Disorders (Drug Abuse) 12/2006
1	Alcoholism (Alcohol Abuse) 12/2006

Drug/Important Bio-Agent (IBA)

17	Antidepressive Agents (Antidepressants)IBA 01/2022 - 02/2005
16	EsketamineIBA 01/2022 - 01/2016
10	Nasal SpraysIBA 01/2022 - 01/2019
2	Ketamine FDA LinkGeneric 08/2016 - 06/2013
2	N-Methylaspartate (NMDA)IBA 08/2016 - 01/2006
2	LithiumIBA 12/2006 - 02/2005
1	Antihypertensive Agents (Antihypertensives)IBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2019
1	Excitatory Amino Acid AntagonistsIBA 08/2016
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 06/2013
1	Biomarkers (Surrogate Marker)IBA 06/2013
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 05/2011
1	Pramipexole (Mirapex)FDA LinkGeneric 05/2011
1	Dopamine Agonists (Dopamine Agonist)IBA 05/2011
1	Antimanic AgentsIBA 09/2007
1	Tamoxifen FDA LinkGeneric 09/2007
1	Protein Kinase CIBA 09/2007
1	Antipsychotic Agents (Antipsychotics)IBA 12/2006
1	Anticonvulsants (Antiepileptic Drugs)IBA 12/2006
1	Memantine (Namenda)FDA Link 01/2006
1	Riluzole FDA LinkGeneric 02/2005
1	Glutamic Acid (Glutamate)FDA Link 02/2005

Therapy/Procedure

2	Secondary Prevention 01/2020 - 01/2019
2	Therapeutics 01/2018 - 01/2006
1	Intravenous Administration 08/2016
1	Vagus Nerve Stimulation 01/2006
1	Deep Brain Stimulation 01/2006